ArticleFrontiers in pharmacology2025

Combining mechanistic quantitative systems pharmacology modeling and patient-derived organoid testing in MET-aberrant non-small cell lung cancer for high-throughput combination efficacy analysis and personalized treatment design.

Jingjing Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.